PDF(Pubmed)
Abstract：
Poorly differentiated sinonasal carcinomas (PDCs) are tumors that have a poor prognosis despite advances in classical treatment. Predictive and prognostic markers and new personalized treatments could improve the oncological outcomes of patients. In this study, we analyzed SOX2 and βIII-tubulin as biomarkers that could have prognostic and therapeutic impacts on these tumors. The cohort included 57 cases of PDCs: 36 sinonasal undifferentiated carcinoma (SNUC) cases, 13 olfactory neuroblastoma (ONB) cases, and 8 sinonasal neuroendocrine carcinoma (SNEC) cases. Clinical follow-up data were available for 26 of these cases. Sox2 expression was detected using immunohistochemistry in 6 (75%) SNEC cases, 19 (53%) SNUC cases, and 6 (46%) ONB cases. The absence of Sox2 staining correlated with a higher rate of recurrence (p = 0.015), especially distant recurrence. The majority of cases showed βIII-tubulin expression, with strong positivity in 85%, 75%, and 64% of SNEC, ONB, and SNUC cases, respectively. Tumors with stronger βIII-tubulin expression demonstrated longer disease-free survival than those with no expression or low expression (p = 0.049). Sox2 and βIII-tubulin expression is common in poorly differentiated sinonasal tumors and has prognostic and therapeutic utility.
摘要：
低分化的鼻窦癌（PDC）是尽管经典治疗方法取得了进展，但预后较差的肿瘤。预测和预后标志物以及新的个性化治疗可以改善患者的肿瘤预后。在这项研究中,我们分析了SOX2和βIII-微管蛋白作为可能对这些肿瘤具有预后和治疗影响的生物标志物.该队列包括57例PDC：36例鼻腔鼻窦未分化癌（SNUC），13例嗅神经母细胞瘤（ONB），鼻窦神经内分泌癌(SNEC)8例。其中26例的临床随访数据可用。在6例（75%）SNEC病例中，采用免疫组化法检测Sox2表达，19（53%）SNUC病例，6例（46%）ONB病例。没有Sox2染色与较高的复发率相关（p=0.015），尤其是远处复发。大多数病例显示βIII-微管蛋白表达，85%的人有很强的积极性，75%,SNEC的64%，ONB,和SNUC案例，分别。具有更强βIII-微管蛋白表达的肿瘤显示出比无表达或低表达的肿瘤更长的无病生存期（p=0.049）。Sox2和βIII-微管蛋白表达在低分化的鼻窦肿瘤中很常见，具有预后和治疗作用。
